162 related articles for article (PubMed ID: 38349234)
1. Antigen Self-Presented Personalized Nanovaccines Boost the Immunotherapy of Highly Invasive and Metastatic Tumors.
Wang T; Han M; Han Y; Jiang Z; Zheng Q; Zhang H; Li Z
ACS Nano; 2024 Feb; 18(8):6333-6347. PubMed ID: 38349234
[TBL] [Abstract][Full Text] [Related]
2. Direct Presentation of Tumor-Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell-Mimicking Nanovaccines.
Zhang J; Fan B; Cao G; Huang W; Jia F; Nie G; Wang H
Adv Mater; 2022 Nov; 34(47):e2205950. PubMed ID: 36217832
[TBL] [Abstract][Full Text] [Related]
3. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
4. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
5. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
6. Rough Nanovaccines Boost Antitumor Immunity Through the Enhancement of Vaccination Cascade and Immunogenic Cell Death Induction.
Zhao X; Zhang J; Chen B; Ding X; Zhao N; Xu FJ
Small Methods; 2023 May; 7(5):e2201595. PubMed ID: 36869418
[TBL] [Abstract][Full Text] [Related]
7. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
[TBL] [Abstract][Full Text] [Related]
8. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
9. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
[TBL] [Abstract][Full Text] [Related]
10. Carbon Dots and Tumor Antigen Conjugates as Nanovaccines for Elevated Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
Small; 2023 Aug; 19(31):e2206683. PubMed ID: 36978241
[TBL] [Abstract][Full Text] [Related]
11. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
12. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
13. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.
Zhang Y; Li Q; Ding M; Xiu W; Shan J; Yuwen L; Yang D; Song X; Yang G; Su X; Mou Y; Teng Z; Dong H
Adv Healthc Mater; 2023 Jul; 12(17):e2203028. PubMed ID: 36807733
[TBL] [Abstract][Full Text] [Related]
14. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
[TBL] [Abstract][Full Text] [Related]
15. Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy.
Luo Z; He T; Liu P; Yi Z; Zhu S; Liang X; Kang E; Gong C; Liu X
Adv Healthc Mater; 2021 Apr; 10(7):e2002080. PubMed ID: 33336537
[TBL] [Abstract][Full Text] [Related]
16. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
17. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
[TBL] [Abstract][Full Text] [Related]
18. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
19. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
20. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]